Orthocell

Orthocell Orthocell is a regenerative medicine company that helps surgeons maximise the body’s natural healing potential.

We have translated deep scientific expertise into clinically proven products for bone, nerve and tendon repair. At Orthocell, we help surgeons maximise the healing potential of the human body. Since 2010, we have applied our deep understanding of regenerative medicine to create products that help surgeons improve patients' quality of life. Our regenerative medicine solutions span treatments for bo

nes, nerves and tendons, and have treated more than 75,000 patients worldwide to date. Our product range supports surgeons to provide the best care for their patients. Remplir™ is a collagen nerve wrap that protects nerves and supports healing. Striate+™ is used for dental guided bone and tissue regeneration. OrthoATI™ and OrthoACI™ are cell therapies for tendon and cartilage repair, respectively. By advancing the science of tissue repair and regeneration, we strive to help patients recover what injury or disease has taken from them by improving mobility, function and performance

🫱Attending ASSH 2026? Register now for this Innovation Forum: Improving Outcomes in Peripheral Nerve Repair: Clinical Ra...
02/09/2026

🫱Attending ASSH 2026?

Register now for this Innovation Forum: Improving Outcomes in Peripheral Nerve Repair: Clinical Rationale, Surgical Challenges, and Early Experience with an Epineurial Substitute.

Ahead of the American Society for Surgery of the Hand Annual Meeting in Boston, we're introducing the faculty joining Orthocell's Innovation Forum lunch.

👨‍⚕️ Dr David Brogan Presenting: The Evolution of Nerve Repair: Why the Next Generation Matters.

📆 Thursday, 17 September | 11:30 am–12:30 pm EDT.

📌 Room 206, Level 2 | John B. Hynes Veterans Memorial Convention Center, Boston.

🍔Register for lunch: https://www.assh.org/annualmeeting/sessions?sid=a13Pb00001X0PKuIAN

Join Orthocell for a hands-on, cadaver-based skills lab featuring Remplir™: https://orthocell.com/assh2026

Visit Orthocell at Booth #1529

*** OCC FY26 Annual Report ***OCC has published its Annual Report for FY26, showcasing several key milestones: • Record ...
31/08/2026

*** OCC FY26 Annual Report ***

OCC has published its Annual Report for FY26, showcasing several key milestones:

• Record revenue of A$13.2 million, up 45% on FY25, including a record June quarter of A$3.8 million.

• Record gross margin of A$6.69 million, up 86% on FY25, primarily due to better margins on Remplir™ products.

• US Remplir™ footprint expanded to 18 distributors across 20+ states, 70 hospitals and 76 surgeons, with access now secured across the US Department of Defense and Veterans Affairs network.

• First commercial Remplir sales in Canada and Hong Kong, with UK and EU market clearance anticipated in the second half of CY2026.

• Platform expanding into new applications, including more than 250 nerve-sparing prostate procedures completed in Australia and a new US regulatory program for SmrtWrap™ tendon repair.

• Stage 1 manufacturing expansion approved, expected to quadruple installed capacity at our Perth facility.

• FY26 closed with A$44.0 million in available funds, no long-term debt and no royalties payable on product sales.

🔗 Read the FY26 OCC Annual Report: https://bit.ly/4x9vqXu

$OCC

28/08/2026

Orthocell were at Gleneagles Hospital Hong Kong today to present on the research and clinical applications of Remplir™, Orthocell's nerve repair technology.

The session provided an excellent opportunity to discuss the growing body of evidence supporting peripheral nerve repair and to share clinical insights with the broader healthcare community.

On behalf of Orthocell, we'd like to thank the team at Gleneagles Hospital Hong Kong for hosting us. We value the opportunity to collaborate with leading clinicians across the region and look forward to continuing our partnership with both the Gleneagles team and our distribution partner, MontsMed.

Thank you for your hospitality, Samantha Stone from Gleneagles, and for helping put this together, Timothy Kang and Vincent Chan from MontsMed.

28/08/2026

Orthocell's Director Commercial APAC Hamish Thrum and Chief Scientific Officer Professor Minghao Zheng, along with Australian Orthopaedic Surgeon Alex Obeirne O'Burn, were at Gleneagles Hospital Hong Kong today to present on the research and clinical applications of Remplir™, Orthocell's nerve repair technology.

The session provided an excellent opportunity to discuss the growing body of evidence supporting peripheral nerve repair and to share clinical insights with the broader healthcare community.

On behalf of Orthocell, we'd like to thank the team at Gleneagles Hospital Hong Kong for hosting us. We value the opportunity to collaborate with leading clinicians across the region and look forward to continuing our partnership with both the Gleneagles team and our distribution partner, MontsMed.

Thank you for your hospitality, Samantha Stone from Gleneagles, and for helping put this together, Timothy Kang and Vincent Chan from MontsMed.

Orthocell's Hamish Thrum, Director of Commercial APAC (pictured), and Trevor Turnbull, Business Development Manager, joi...
25/08/2026

Orthocell's Hamish Thrum, Director of Commercial APAC (pictured), and Trevor Turnbull, Business Development Manager, joined the WA orthopaedic community at the 54th Australian Orthopaedic Association WA Annual Scientific Meeting at Bunker Bay over the weekend.

The meeting featured a strong scientific programme and plenty of discussion on emerging research and innovation in orthopaedic surgery.

The team had the opportunity to learn about Dr Rui Ruan’s research investigating a photo-crosslinkable bioadhesive collagen patch for sutureless neural tissue repair, including its potential applications in orthopaedic surgery.

The research highlights ongoing developments in collagen-based biomaterials and their potential role in supporting tissue repair and regeneration.

Remplir™ has now arrived in Ukraine. The latest humanitarian delivery to support Ukrainian surgeons treating traumatic n...
20/08/2026

Remplir™ has now arrived in Ukraine. The latest humanitarian delivery to support Ukrainian surgeons treating traumatic nerve injuries is now on the ground and ready for use.

Dr Zakhar Plakhtyr (pictured below) receives this delivery of Remplir™ medical devices, helping provide surgeons with access to advanced peripheral nerve repair technology for victims of war suffering severe nerve injuries as a result of the ongoing conflict.

We thank the Australian organisations and donors who helped make this shipment possible, and the Ukraine Crisis Appeal for coordinating support on the ground.

This initiative reflects Orthocell Ltd's ongoing commitment to supporting healthcare professionals and improving outcomes for those impacted by the ongoing conflict.

Congratulations to Ramsay Health Care Limited on the opening of the Ramsay Surgical Centre Cleveland in Queensland today...
17/08/2026

Congratulations to Ramsay Health Care Limited on the opening of the Ramsay Surgical Centre Cleveland in Queensland today. We are proud that the first procedure was a tendon biopsy, performed by Dr Christopher Conyard (left), with support from Orthocell clinical team member Ellis Taylor.

Orthocell is proud to be part of Australia’s growing regenerative medicine sector, developing and manufacturing innovative cell therapies and medical devices that harness the body’s own capacity for tissue repair and regeneration. It’s exciting to see our clinical network continue to expand, helping bring Australian regenerative medicine expertise to more clinicians and patients.

Read more about Orthocell autologous cell therapies here: https://orthocell.com/au/solutions/cell-therapies/

Orthocell's growth story is reaching Boston's global investor stage. Tonight, CEO and Managing Director Paul Anderson pr...
12/08/2026

Orthocell's growth story is reaching Boston's global investor stage.

Tonight, CEO and Managing Director Paul Anderson presents live at the Canaccord Genuity 46th Annual Growth Conference, one of the largest gatherings of institutional investors and growth companies in the world.

The presentation gives Orthocell direct access to a broader base of global investors, updating delegates on the Company's US commercialisation progress, including its growing surgeon and hospital network, and Orthocell's broader ambition to establish itself as a genuine competitor in the international regenerative medicine and medical device sector.

💻 Live webcast: 10.30am Eastern Time / 10.30pm AWST, Wednesday 12 August
🔗 Register: https://bit.ly/3Sabe98
A replay will be available under Investors – Latest News at orthocell.com

$OCC

Hamish Thrum and Ellis Taylor are at the Australian Orthopaedic Association (AOA) Queensland Branch Annual Scientific Me...
08/08/2026

Hamish Thrum and Ellis Taylor are at the Australian Orthopaedic Association (AOA) Queensland Branch Annual Scientific Meeting in Noosa this weekend.

It has been an engaging meeting so far, featuring high-quality scientific discussions and the chance to connect with Orthopaedic Surgeons to share information on OrthoATI™, our autologous tenocyte injection therapy for chronic, treatment-resistant tendon injuries, as well as OrthoACI™, our autologous chondrocyte implantation therapy developed to regenerate damaged articular cartilage.

We also have samples of Remplir™, distributed in Australia by Device Technologies, so that surgeons can experience the superior handling characteristics, flexibility, and elasticicity of our collagen epineurial substitute designed to protect the coaptation site and help prevent axonal escape.

If you are at the meeting, come over and meet the Orthocell team.

This week Orthocell was at Tampa General Hospital providing Remplir™ nerve repair devices and instruction on nerve surge...
07/08/2026

This week Orthocell was at Tampa General Hospital providing Remplir™ nerve repair devices and instruction on nerve surgery techniques, training Orthopaedic Residents and Hand Surgery Fellows. Thanks Dr Michael Doarn from the Florida Orthopaedic Institute and everyone else who was involved in making this a successful week of training.

Address

Building 191 Murdoch University South Street
Perth, WA
6150

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Website

, , ,

Alerts

Be the first to know and let us send you an email when Orthocell posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Orthocell:

Shortcuts

Share

Category